Dermata Therapeutics
DRMA
13 hedge funds and large institutions have $158K invested in Dermata Therapeutics in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
86% more funds holding
Funds holding: 7 → 13 (+6)
23% more capital invested
Capital invested by funds: $129K → $158K (+$29.2K)
0.4% more ownership
Funds ownership: 2.65% → 3.05% (+0.4%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.6K |
| 4 |
AA
Advisory Alpha
Holland,
Michigan
|
+$12.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$35.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$23.7K |
| 3 |
Citigroup
New York
|
-$1 |
DRMA Hedge Fund Activity: Q2 2026 in Review
13 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q2 2026, worth a combined $158K — up 23% from $129K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new DRMA positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $23.6K. The largest seller was Geode Capital Management, cutting an estimated $35.4K.
- 13 institutional investors held Dermata Therapeutics (DRMA) as of Q2 2026, up from 7 in Q1 2026.
- Funds reported $158K of Dermata Therapeutics stock for Q2 2026, up 23% quarter-over-quarter.
- 7 funds opened new Dermata Therapeutics positions in Q2 2026 and 1 closed out, a net change of +6 holders.
- The largest Dermata Therapeutics buyer in Q2 2026 was State Street, an estimated $23.6K added.
- The largest Dermata Therapeutics seller in Q2 2026 was Geode Capital Management, an estimated $35.4K sold.
Based on aggregated 13F filings for Q2 2026.